Loading patent…
AssigneeMerck & Co., Inc.
InventorsPeter J. Kniskern, William J. Miller, Arpi Hagopian, Charlotte C. Ip, John P. Hennessey, Jr., Dennis J. Kubek, Pamela D. Burke
Estimating the term…
Type-specific capsular polysaccharide preparations from Streptococcus pneumoniae, having on average less than about 1000 oligosaccharide repeat units per molecule, polydispersities between 1.0 and 1.4, intrinsic viscosities between 0.6 and 3.0 dL/g, and less than 3% contamination of type-specific polysaccharide by group-specific C-polysaccharide, are produced by a novel process. The novel type specific polysaccharide products are useful in the preparation of vaccines, especially covalent conjugates comprising the novel polysaccharide linked to a T-cell stimulatory carrier protein. Vaccines comprising the novel polysaccharides are useful in the prevention of infection and of diseases associated with infection by Streptococcus pneumoniae.
A process for making a size-reduced capsular polysaccharide of Streptococcus pneumoniae of serotype 6B having decreased polydispersity which comprises:
A process for making a size reduced capsular polysaccharide of Streptococcus pneumoniae of serotype 14 having decreased polydispersity which comprises:
A process for making a size reduced capsular polysaccharide of Streptococcus pneumoniae of serotype 23F having decreased polydispersity which comprises:
A process for making a size reduced capsular polysaccharide of Streptococcus pneumoniae of serotype 18C having decreased polydispersity which comprises:
A process for making a size reduced capsular polysaccharide of Streptococcus pneumoniae of serotype 4 having decreased polydispersity which comprises:
A process for making a size reduced capsular polysaccharide of Streptococcus pneumoniae of serotype 9V having decreased polydispersity which comprises:
Dependencies are inferred from the claim text.